# Role of Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays in the Resistance of Non-small Cell Lung Cancer to Anti-PD1/PD-L1 Therapies

> **NCT06024538** · — · NOT_YET_RECRUITING · sponsor: **University Hospital, Bordeaux** · enrollment: 25 (estimated)

## Conditions studied

- Lung Neoplasm
- Cancer Associated Fibroblast
- Myeloid-Derived Suppressive Cells Immunosuppression

## Interventions

- **PROCEDURE:** Tumor samples

## Key facts

- **NCT ID:** NCT06024538
- **Lead sponsor:** University Hospital, Bordeaux
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06024538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06024538, "Role of Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays in the Resistance of Non-small Cell Lung Cancer to Anti-PD1/PD-L1 Therapies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06024538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*